SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> <u>FMR LLC</u>			2. Date of Event Requiring Statement Month/Day/Year) 10/22/2015	3. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Coherus BioSciences, Inc.</u> [ CHRS ]				
(Last) 245 SUMMI (Street) BOSTON (City)	(First) ER STREET MA (State)	(Middle) 02210 (Zip)		4. Relationship of Reporting Perse (Check all applicable) Director X Officer (give title X See Remark	10% Owner Other (speci below)	(Moi	hth/Day/Year) dividual or Joint icable Line) G Form filed b	ate of Original Filed /Group Filing (Check y One Reporting Person y More than One erson
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct or Indirect (I) (Instr. 5)	(D) (Instr	4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Common Stock				109,478 <sup>(1)</sup>	I	Beacon Bioventures Fund III Limit Partnership <sup>(2)</sup>		es Fund III Limited
Common Stock				400,188(1)	I	Impr	esa Fund III	Limited Partnership <sup>(3)</sup>
Common Stock				528 <sup>(1)</sup>	I	F-Prime Inc. <sup>(4)</sup>		
Table II - Derivative Securities Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable a Expiration Date (Month/Day/Year)	nd 3. Title and Amount of Securi Underlying Derivative Securi	ty (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. Table I, Column 2 does not include shares beneficially owned by FMR Co., Inc. and Pyramis Global Advisors Trust Company as a result of acting as investment adviser to various investment companies and accounts as disclosed in Remark 2 below.

Title

Expiration

Date

2. Beacon Bioventures Advisors Fund III Limited Partnership is the general partner of Beacon Bioventures Fund III Limited Partnership. Beacon Bioventures Advisors Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the family of Edward C. Johnson 3d.

3. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the family of Edward C. Johnson 3d.

4. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.

## **Remarks:**

Remark 1: Edward C. Johnson 3d is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Edward C. Johnson 3d and Abigail P. Johnson is c'o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: In addition to the securities shown in Table I, FMR Co., Inc., an indirect wholly-owned subsidiary of FMR LLC and a investment adviser registered under the Investment Advisers Act of 1940, and Pyramis Global Advisors Trust Company, an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1940, are the beneficial owners of 3,428,871 shares, or 8.9532%, of Common Stock of Coherus BioSciences, Inc., as a result of acting as investment adviser to various investment companies registered under the Investment Company Act of 1940, institutional accounts and other collective investment vehicles. FMR LLC, Edward C. Johnson 3d and Abigail P. Johnson is c'o FMR LLC, advisers Act of 1940, and Pyramis Global Advisors Trust Company, an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1940, are the beneficial owners of 3,428,871 shares, or 8.9532%, of Common Stock of Coherus B

Marc R. Bryant, Dulyauthorized under Powers ofAttorney, by and on behalf ofFMR LLC and its direct andindirect subsidiaries, EdwardC. Johnson 3d and Abigail P.Johnson

of

Shares

10/29/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

Exercisable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.